Drug Profile
Research programme: repulsive guidance molecule A modulators - AbbVie
Alternative Names: RGMa - AbbottLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Abbott Laboratories
- Developer AbbVie
- Class
- Mechanism of Action Membrane glycoprotein modulators; Nerve tissue protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Neurological disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Neurological-disorders in USA
- 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie